SCHEMBL3220973

SCHEMBL3220973

CN1CCN(c2ccc3ccccc3c2)c2ccc(-c3ccccn3)cc2C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.49
HTR3A P46098 1/20 0.44
SLC6A2 P23975 2/20 0.40
SLC6A3 Q01959 2/20 0.40
DRD2 P14416 1/20 0.40
METAP1 P53582 1/20 0.40
DYRK1A Q13627 2/20 0.40
GSK3B P49841 1/20 0.40
SLC6A4 P31645 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 1/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
XBP1 P17861 1/20 0.38
RAB9A P51151 1/20 0.38
KLF5 Q13887 1/20 0.38
RAD52 P43351 1/20 0.37
CXCR1 P25024 1/20 0.37
DHFR P00374 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3479598 0.89 HTR3A (0.46) SCN9AHTR3ASLC6A2SLC6A3DRD2
SCHEMBL3230207 0.89 SLC6A2 (0.46) SCN9AHTR3ASLC6A2SLC6A3DYRK1A
SCHEMBL3220403 0.88 SCN9A (0.51) SCN9ADRD2METAP1DYRK1AGSK3B
SCHEMBL3479582 0.87 SLC6A2 (0.55) SCN9AHTR3ASLC6A2SLC6A3SLC6A4
SCHEMBL3238925 0.86 SCN9A (0.48) SCN9ADRD2METAP1DYRK1AGSK3B
SCHEMBL3231955 0.86 SCN9A (0.55) SCN9AHTR3ASLC6A2SLC6A3SLC6A4
SCHEMBL3223902 0.86 SCN9A (0.46) SCN9ASLC6A2SLC6A3DRD2METAP1
SCHEMBL3240469 0.86 SCN9A (0.50) SCN9ADRD2METAP1DYRK1AGSK3B
SCHEMBL3224959 0.86 SCN9A (0.52) SCN9ADRD2METAP1SMN1; SMN2ALDH1A1
SCHEMBL3235442 0.84 SCN9A (0.46) SCN9AHTR3ADRD2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885HTR3A 30/4885SLC6A2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.